Author:
Al-Rousan Rabaa M.,Rice Kevin M.,Katta Anjaiah,Laurino Joseph,Walker Ernest M.,Wu Miaozong,Triest William E.,Blough Eric R.
Subject
Biochemistry (medical),Public Health, Environmental and Occupational Health,General Medicine,Physiology (medical)
Reference29 articles.
1. Iron-induced cardiac damage: role of apoptosis and deferasirox intervention;Wang;J Pharmacol Exp Ther,2011
2. Secondary iron overload;Kushner;Hematology Am Soc Hematol Educ Program,2001
3. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major;Brittenham;N Engl J Med,1994
4. Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial;Vichinsky;Acta Haematol,2008
5. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload;Piga;Haematologica,2006
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献